SecBot SecBot

ARWR drug pipeline

$47.78
+1.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.9%
1-day, median of 6 events
IV rank
41
IV 65% · HV 61%
Rated drugs
6
1 bullish · 1 mixed · 4 neutral
Phase 3 trials
5
2 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseApproved (US, FCS); Phase 3 (severe hypertriglyceridemia) ongoing; EU under review
Time to marketAlready approved and launched in the US (FDA, November 2025) for FCS. EU decision expected ~2026; SHTG label expansion ~2027 if the Phase 3 readout is positive.

Redemplo plozasiran Updated Aug 2

What to watch

The main re-rating event for ARWR is the Phase 3 severe-hypertriglyceridemia (SHTG) topline readout, expected around mid-September 2026 per trial estimates, SHTG is a far bigger market than the ultra-rare FCS indication Redemplo was approved for. Also watch the Aug 4, 2026 earnings call for the first real Redemplo launch revenue commentary, the pending EU decision after the April 2026 CHMP opinion, and direct competition from Ionis' olezarsen (which had its own FDA decision date for SHTG on June 30, 2026).

Bull case
  • FDA-approved commercial product: FDA approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with FCS (NDA; approval press-release 8-K filed Nov 25, 2025), and stored catalyst-outcome data shows ARWR +30.4% on the 1-day move ($44.26 → $57.71) around that catalyst.
  • Breakthrough Therapy designation for severe hypertriglyceridemia (TG ≥500 mg/dL) granted Feb 5, 2026, pointing to an accelerated path into a much larger market than FCS.
  • Two pivotal Phase 3 SHTG trials (n=446 and n=311) are active/not-recruiting with estimated completion Sept 2026, the big near-term re-rating catalyst.
Bear case
  • FCS is an ultra-rare disease, so the approved indication alone is a small revenue base; Q3 2026 revenue is only estimated at ~$55.4M and the commercial ramp is unproven.
  • Binary readout risk: the SHTG Phase 3 topline results are the main driver of the next leg, and a miss would hit the stock hard.
  • Direct competition: Ionis' olezarsen had its own FDA decision date for severe hypertriglyceridemia under Priority Review on June 30, 2026 (per stored PDUFA catalyst data), a head-to-head rival in the expansion indication.
▲ bullish
Impact
PhasePhase 1/2a
Time to marketA Phase 1/2a SAD portion is complete and the MAD portion is enrolling; assuming positive data, Phase 2/3 would likely follow. Commercial approval, if successful, is likely several years away (3+ years).

ARO-DIMER-PA Updated Nov 15

What to watch

ARO-DIMER-PA delivered promising Phase 1 SAD data at AHA 2026, validating Arrowhead's dual-gene RNAi platform, but the stock is down 50% from its 52-week high amid institutional selling and pre-commercial cash-burn concerns. The next catalyst is the MAD portion data, which will test durability and safety of repeat dosing. With a mean analyst price target of $106 implying 122% upside, sentiment is bullish on the pipeline broadly, but no binary catalyst is imminent.

Bull case
  • ARO-DIMER-PA achieved clinical validation of Arrowhead's novel dimeric RNAi platform, demonstrating deep and durable dual-gene silencing from a single injection, with mean maximal reductions of 72% in PCSK9 and 88% in APOC3 in Phase 1 SAD data (BusinessWire, Sept 15, 2026).
  • At AHA 2026, ARO-DIMER-PA showed mean LDL-C reductions up to 65% and median triglyceride reductions up to 78%, which compare favorably to existing PCSK9 and APOC3 inhibitors that each target only one of the two pathways; the dual mechanism could become a best-in-class approach for mixed hyperlipidemia (TechTimes, Nov 7, 2026).
  • Analyst consensus is strongly bullish on ARWR: 20 analysts rate it Buy/Strong Buy with a mean price target of $106 (122% upside from $47.78), and RBC Capital and Stifel both reiterated positive ratings on Nov 13, 2026.
Bear case
  • ARO-DIMER-PA is very early stage (Phase 1/2a), with only single-dose data available; durability, safety at repeat dosing, and proof of cardiovascular outcomes are entirely unproven and represent significant clinical risk.
  • The PCSK9 inhibitor market is already crowded with approved biologics (Amgen's Repatha, Regeneron/Sanofi's Praluent) and oral alternatives in development; APOC3 antisense drugs from Ionis (olezar sen / TQJ230, now Novartis) are also in late-stage development, creating substantial competition.
  • ARWR stock has fallen roughly 50% from its 52-week high of $95.49 to $47.78; despite positive ARO-DIMER-PA data, the stock sold off on September 15, 2026 (sell-the-news reaction), suggesting high expectations were already priced in.
● neutral
Impact
PhasePhase 1/2a
Time to marketStill several years away. The drug is in Phase 1/2a, and assuming successful development, would require at least one later-stage Phase 2b and a Phase 3 program before any regulatory filing, likely 4+ years from now.

ARO-INHBE Updated Nov 15

What to watch

Watch for the next interim Phase 1/2a readout on ARO-INHBE, which could provide longer-term durability and safety data in both monotherapy and tirzepatide-combination arms. Also track Wave Life Sciences' WVE-007 (INHBE siRNA) Phase 2a data, as it is the most advanced direct competitor and could derisk or crowd the target. Arrowhead's broader pipeline catalysts (plozasiran commercialization, ARO-MAPT, ARO-DIMER-PA) may move ARWR stock more than ARO-INHBE in the near term.

Bull case
  • ARO-INHBE achieved approximately double the weight loss of tirzepatide alone (-9.4% vs -4.8% at 16 weeks) in obese T2D patients, a clinically meaningful additive effect suggesting a complementary mechanism.
  • The drug targets a genetically validated human obesity target (INHBE loss-of-function variants are associated with healthier fat distribution and lower metabolic disease risk), which may translate to a more favorable body-composition profile with muscle preservation.
  • Interim data showed robust fat reduction and liver fat improvements in MASH, expanding the addressable market beyond weight loss.
Bear case
  • ARO-INHBE is still in very early clinical development (Phase 1/2a); many RNAi drugs fail to replicate early signals in larger, longer trials.
  • The INHBE space is becoming crowded: Wave Life Sciences (WVE-007) is already in Phase 2a, and Rona Therapeutics and Vial have INHBE siRNA programs, potentially eroding Arrowhead's first-mover advantage.
  • The 16-week combination data, while promising, had a small sample size, and the durability and long-term safety beyond 16 weeks are unknown.
● neutral
Impact
PhasePhase 1/2a
Time to marketAt least 4-6 years away from potential approval if successful. The drug is in Phase 1/2a, Part 2 (Alzheimer's patients) is enrolling, and additional larger trials would be needed before any regulatory filing.

ARO-MAPT Updated Nov 15

What to watch

The next catalyst for ARO-MAPT is Part 2 of the ongoing Phase 1/2a study, which is enrolling patients with Alzheimer's disease and other tauopathies. No firm readout date has been given, but given healthy-volunteer enrollment began in early 2026, patient data could emerge in late 2027 or 2028. Part 2 data showing tau reduction translates to cognitive or functional benefit would be a major positive for the TRiM CNS platform; failure to differentiate from Biogen/Ionis' diranersen or a poor safety signal in patients would be a setback.

Bull case
  • Interim Phase 1/2a data showed up to 73% reduction in cerebrospinal fluid tau in healthy volunteers across three dose levels (2.1, 6.4, and 12.8 mg/kg), described as deep and durable with no serious adverse events a positive early safety signal.
  • ARO-MAPT uses Arrowhead's TRiM platform for subcutaneous delivery across the blood-brain barrier, a key differentiator versus the intrathecal delivery required by Biogen's diranersen, potentially offering a more convenient administration route.
  • Analyst consensus is strongly bullish: 20 buy/strong buy ratings, 1 hold, 0 sell, with a mean price target of ~$106 (122% implied upside from ~$47.78). Morgan Stanley added to its position (+69%) in Q3 2026.
Bear case
  • Part 2 of the Phase 1/2a study in Alzheimer's patients has no firm readout date and could take 12-24 months. Clinical validation in patients (not just healthy volunteers) is unproven.
  • The tau-lowering space is increasingly competitive: Biogen/Ionis' diranersen (an antisense oligonucleotide) posted positive Phase 2 CELIA data in July 2026 showing tau reduction and cognitive signals at AAIC 2026, setting a high bar.
  • ARWR stock has fallen sharply from ~$87 in August 2026 to ~$47 in November 2026 despite positive data, with notable insider sales (~$1M by director Perry and ~$174K by director Olukotun both in August) and several institutional exits/trims in Q3 2026, including complete exits by 1832 Asset Management and HRT Financial.
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 YOSEMITE trial succeeds, an NDA submission could follow in late 2027 or 2028, with potential FDA approval in 2028 or later. The timeline depends on the duration of the treatment and follow-up period in the HoFH study.

zodasiran Updated Nov 15

What to watch

The next major catalyst for zodasiran is the topline data readout from the Phase 3 YOSEMITE study in HoFH. Enrollment was completed in July 2026; a 24- to 48-week treatment period would likely push data into the second half of 2027 or 2028. Positive results would set up an NDA filing for an ultra-rare indication with a clear path to market, while negative or modest results would undermine the asset's thesis given that evinacumab already exists as an approved ANGPTL3-directed therapy.

Bull case
  • Phase 2b ARCHES-2 data in mixed hyperlipidemia, published in the New England Journal of Medicine, showed zodasiran produced robust reductions in triglycerides (up to 59%), LDL-C (up to 32%), and ANGPTL3 (up to 71%) with a favorable safety profile. Zodasiran is a subcutaneously injected RNAi therapeutic, which could offer dosing convenience over evinacumab's IV infusion regimen and potentially capture share in the HoFH market. Arrowhead has a strong analyst consensus (20 Buy/Strong Buy vs 1 Hold, mean price target $106 vs $47.78 current price) with multiple firms reiterating Buy ratings after the November 2026 earnings. The YOSEMITE Phase 3 study completed enrollment in under 13 months, suggesting robust investigator and patient interest in an ultra-rare disease with high unmet need.
Bear case
  • Evinacumab (Evkeeza), a monoclonal antibody targeting ANGPTL3, is already approved for HoFH in adults, adolescents, and children as young as one year, giving zodasiran a significant commercial disadvantage in an ultra-rare market. Phase 3 YOSEMITE readout is likely more than 12 months away (enrollment completed July 2026), leaving no near-term binary catalyst to drive the stock. Arrowhead shares fell ~15% in November 2026 after rival Ionis cut its Tryngolza forecast, signaling concern about the broader severe hypertriglyceridemia market that could also affect how investors view zodasiran's commercial prospects. Multiple institutional holders trimmed or exited ARWR in Q3 2026, and two directors sold shares in August 2026 above $86, well above the current ~$48 price.
● neutral
Impact
PhasePhase 1/2a
Time to marketAssuming successful clinical development, ARO-ALK7 is likely 5+ years away from potential approval, as it is still in early Phase 1/2a with no pivotal trial initiated.

ARO-ALK7 Updated Nov 15

What to watch

Watch for additional interim data from the Phase 1/2a AROALK7-1001 study, which could come at future medical meetings or investor events. The Roche-Rona ALK7 deal (up to $1.16B) validated the target in October 2026, reducing Arrowhead's technical risk. However, ARO-ALK7 remains an early-stage program within a diversified pipeline; ARWR's nearer-term catalysts are plozasiran, ARO-DIMER-PA, ARO-MAPT, and ARO-INHBE data.

Bull case
  • A January 2026 interim readout showed ARO-ALK7 is the first RNAi therapeutic to achieve adipocyte gene target silencing, with mean ALK7 mRNA reductions of -88% at the 200 mg dose at week 8 and maximum of -94% (n=4).
  • Roche licensed an ALK7-targeting RNAi from Rona Therapeutics in October 2026 for up to $1.16 billion, providing strong external validation of the ALK7 target in obesity.
  • ARO-ALK7 targets a novel mechanism (blocking ALK7 signaling that suppresses fat breakdown) that could preserve lean muscle mass better than GLP-1 agonists.
Bear case
  • ARO-ALK7 is early stage (Phase 1/2a) with no pivotal or registrational data; clinical failure could wipe out its value.
  • The obesity market is intensely competitive, with GLP-1 drugs from Novo Nordisk and Eli Lilly dominating, plus numerous other mechanisms in development.
  • Arrowhead's stock has fallen from a 52-week high of $95.49 to $47.78 as of November 13, 2026, reflecting significant share price decline.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Feb 5, 2026RedemploBreakthrough designation−5.2%−8.3%
Nov 25, 2025RedemploApproval+30.4%+47.0%
Nov 18, 2025RedemploBreakthrough designation−2.9%+16.5%
Nov 18, 2025RedemploFast Track−2.9%+16.5%
Nov 18, 2025RedemploApproval−2.9%+16.5%
Nov 18, 2025RedemploOrphan drug designation−2.9%+16.5%

Clinical trials

13 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Plozasiran InjectionStudy of Plozasiran in Adults With Severe HypertriglyceridemiaPhase 3Completed311Jun 17, 2026
Plozasiran InjectionStudy of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaPhase 3Completed446Jun 12, 2026
Plozasiran InjectionPhase 3 Study of Plozasiran in Adults With HypertriglyceridemiaPhase 3Completed1,456Jun 1, 2026
RedemploStudy of ARO-APOC3 in Adults With DyslipidemiaPhase 2Completed418Sep 22, 2025
ARO-C3Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseasePhase 2Completed62Sep 10, 2025
ARO-MMP7 Inhalation SolutionStudy of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisPhase 2Completed · results105Sep 5, 2025
ARO-RAGEStudy of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseasePhase 2Completed127Apr 16, 2025
RedemploA Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia SyndromePhase 3Completed · results37Nov 26, 2024
ARO-MUC5ACStudy of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseasePhase 2Terminated · results78Nov 12, 2024
RedemploStudy of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)Phase 3Completed · results75Apr 29, 2024
ARO-ANG 3 InjectionStudy of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)Phase 2Terminated · results18May 2, 2023
RedemploStudy to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaPhase 2Completed · results229Mar 9, 2023
RedemploStudy of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaPhase 2Completed · results353Feb 10, 2023